NALIRIFOX (Onivyde (nanoliposomal irinotecan component))

Description

NALIRIFOX is a triplet chemotherapy regimen that combines nanoliposomal irinotecan (nal-IRI), leucovorin, fluorouracil, and oxaliplatin for the treatment of metastatic colorectal cancer. This regimen represents an intensified approach to first-line treatment, particularly in patients with KRAS-mutated tumors where targeted therapy options are more limited. NALIRIFOX delivers enhanced drug exposure through the nanoliposomal formulation of irinotecan while maintaining the proven efficacy of the FOLFOX backbone. The regimen is designed for patients with good performance status who can tolerate intensive combination chemotherapy.

Mechanism of Action

The regimen combines multiple mechanisms of cytotoxic action against colorectal cancer cells. Nanoliposomal irinotecan provides sustained release of the topoisomerase I inhibitor irinotecan, causing DNA strand breaks during replication, while oxaliplatin forms DNA crosslinks as a platinum-based alkylating agent. Fluorouracil acts as a pyrimidine antimetabolite that disrupts DNA and RNA synthesis, with leucovorin enhancing its activity by stabilizing the inhibitory complex with thymidylate synthase.

Molecular Targets

Side Effects

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials